AI assistant
Intrasense — Board/Management Information 2026
Jan 9, 2026
1447_iss_2026-01-09_f2715496-74a6-4df6-b526-c16c0d3cc611.pdf
Board/Management Information
Open in viewerOpens in your device viewer
intrasense
Reveal the invisible. Save lives.
CHANGE IN GENERAL MANAGEMENT
Montpellier, January 9, 2026, 5:45 PM: Intrasense (ISIN: FR0011179886), a French expert in medical imaging solutions that facilitate and secure diagnostics, decision-making, and therapeutic follow-up, announces the appointment of Mr. Stephen Armand as Chief Executive Officer of the Company.
Mr. Stephen Armand replaces Mr. Alexandre Salvador, who is leaving the company to pursue new projects. The Board of Directors thanks him for the work accomplished since he joined Intrasense in August 2024.
Mr. Stephen Armand joined Intrasense in June 2025 as Chief Financial and Administrative Officer. An expert in financial management and organizational transformation within international groups, he brings over 20 years of experience to structure the company's development and support its growth ambitions. He has an excellent understanding of the company's current challenges, both financial, operational, and commercial.
Supported by the Board of Directors, Mr. Stephen Armand can count on the support and experience of the Intrasense Executive Committee to ensure a smooth transition and continue implementing transformation measures and deploying the company's strategy.
Next event:
2025 ANNUAL REVENUE
February 5, 2026, after market close
About Intrasense
A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.
Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AIs, optimizes the longitudinal monitoring of cancer patients.
By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management.
More information on www.intrasense.fr
Press Release
intrasense
intrasense
Reveal the invisible. Save lives
Contacts
INTRASENSE
Communication officer
Salomé Sylvestre
Phone: +334 67 13 01 30
[email protected]
SEITOSELACTIFIN
Analyst & Investor Relations
Foucauld Charavay
Phone: +336 37 83 33 19
[email protected]
Press Relations
Isabelle Dray
Phone: +331 56 88 11 29
[email protected]
Press Release
intrasense